Long COVID: Microclots May Be the Key

Millions globally continue to experience the debilitating effects of long COVID, a complex condition with a wide range of symptoms appearing after initial infection. Despite growing numbers of affected individuals, a definitive biomarker for diagnosis remains elusive, complicating research and patient care.

Research suggests that the SARS-CoV-2 spike protein may induce severe clotting pathology, leading to the formation of microclots within the bloodstream. While some individuals clear these clots, they can persist in others, potentially damaging blood vessels and impeding organ function. This widespread inflammation and compromised blood flow may underlie the diverse and systemic symptoms characteristic of long COVID.

A significant challenge in managing long COVID is the lack of a reliable diagnostic test. Standard blood workups often return normal results, leaving patients without a clear explanation for their persistent symptoms. Scientists are now focused on developing a test to detect high levels of microclots and hyperactivated platelets, which have been consistently observed in long COVID patients.

This novel approach holds promise not only for diagnosing long COVID but also for guiding treatment strategies. If microclots are confirmed as a reliable biomarker, they could become a target for therapies aimed at clearing them. This research is being funded, in part, through crowdfunding, highlighting the urgent need for faster research into this persistent post-viral illness.